Novel reagent for tumour imaging and therapy

摘要

Novel oligopeptides are disclosed for in vivo tumour imaging and therapy. The novel oligopeptides are oligopeptides containing from 4 to 50 peptide units containing as a characteristic triplet therein the amino acid sequence leu-asp-val (LDV), which triplet provides the oligopeptide with a strong in vivo binding affinity for LDV binding sites on tumours and other tissues. For diagnostic purposes the oligopeptides are labelled with a radioactive label, e.g. <1><2><5>I, whilst for therapeutic purposes the oligopeptides are chemically linked to or conjugated with a cytotoxin, such as the ricin A-chain.